The fight against cancer increasingly emphasizes prevention and timely intervention as critical components of improving patient survival rates. Central to this effort is Early Detection & Screening, which enable clinicians to identify malignancies before they progress to advanced, less treatable stages. Advances in imaging technologies, molecular diagnostics, and genomic profiling have significantly enhanced the sensitivity and accuracy of cancer screening programs. These innovations make it possible to detect tumors at the cellular or molecular level, often before symptoms appear, allowing for earlier therapeutic intervention and better prognoses. Public health initiatives focused on awareness, risk assessment, and regular screening have also proven essential in reducing the global cancer burden by promoting proactive health management.
The importance of Early Detection & Screening continues to grow as research expands into biomarkers, artificial intelligence–driven diagnostics, and liquid biopsy technologies. These emerging tools are making screening more precise, less invasive, and accessible to a broader population. Early detection not only saves lives but also reduces treatment complexity, cost, and long-term side effects by enabling curative therapies at initial disease stages. Integrating these advanced screening methods into precision oncology frameworks ensures a comprehensive approach to cancer prevention and management. As innovation progresses, early detection strategies will remain a cornerstone of global cancer control, offering the greatest opportunity to improve patient outcomes and reduce mortality rates.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation